Tests modified immune T cells against CD33 in adults with acute myeloid leukemia

Trial details

Who runs it

City of Hope Medical Center

Trial code

NCT05672147

Record updated

9 November 2026

Original description

This phase I trial tests the safety, side effects, and the best dose of anti-CD33 chimeric antigen receptor (CAR) T-Cell therapy in treating patients with acute myeloid leukemia that has come back (recurrent) or does not respond to treatment (refractory). CAR T-cell therapy is a type of treatment in which a patient or donor's T cells (a type of immune system cell) are changed in the laboratory so they will attack cancer cells. T cells are taken from a patient's or donor's blood. Then the gene for a special receptor that binds to a certain protein on the patient's cancer cells is added to the T cells in the laboratory. The special receptor is called a chimeric antigen receptor. Large numbers of the CAR T cells are grown in the laboratory and given to the patient by infusion for treatment of certain cancers.Read full original descriptionShow less

Phase I Study of Cellular Immunotherapy Using T Cells Lentivirally Transduced to Express a Cd33-Specific Chimeric Antigen Receptor for Patients With Cd33+ Relapsed/Refractory Acute Myeloid Leukemia

This phase I trial tests the safety, side effects, and the best dose of anti-CD33 chimeric antigen receptor (CAR) T-Cell therapy in treating patients with acute myeloid leukemia that has come back (recurrent) or does not respond to treatment (refractory). CAR T-cell therapy is a type of treatment in which a patient or donor's T cells (a type of immune system cell) are changed in the laboratory so they will attack cancer cells. T cells are taken from a patient's or donor's blood. Then the gene for a special receptor that binds to a certain protein on the patient's cancer cells is added to the T cells in the laboratory. The special receptor is called a chimeric antigen receptor. Large numbers of the CAR T cells are grown in the laboratory and given to the patient by infusion for treatment of certain cancers.

Inclusion: Documented informed consent of the participant and/or legally authorized representative; Assent, when appropriate, will be obtained per institutional guidelines; For research participants who do not speak English, a short form consent may be used with a City of Hope (COH) certified interpreter/translator to proceed with screening, while the request for a translated full consent is processed; Agreement to allow the use of archival tissue from diagnostic tumor biopsies; If unavailable, exceptions may be granted with Study principal investigator (PI) approval; Age: >= 18 years; Karnofsky Performance Scale (KPS) >= 70; Life expectancy >= 16 weeks at the time of enrollment; Prior allogeneic transplant allowed if > 6 months prior to study enrollment; Participant must have a confirmed diagnosis of active CD33+ AML de novo, or secondary OR participants who are at a high risk for disease recurrence; Relapsed AML is defined as patients that had a first complete response (CR) before developing recurrent disease (increased bone marrow blasts); Refractory AML is defined as patients that have not achieved a first CR after induction chemotherapy. For patients with AML evolving from myelodysplastic syndrome, they should have completed at least one cycle of induction chemotherapy; Research participants must have bone marrow and/or peripheral blood samples available for confirmation of diagnosis of AML; CD33 positivity must be confirmed by either flow cytometry or immunohistochemistry within 90 days of study entry. Cytogenetics, flow cytometry, and molecular studies (such as FLT-3 status) will be obtained as per standard practice; Research participants who are at a high risk of disease recurrence, they must have historical bone marrow and/or peripheral blood samples available for confirmation of diagnosis of AML; No known contraindications to lymphodepleting agents, steroids, tocilizumab and/or cetuximab, or the investigational agent; Total serum bilirubin =< 2.0 mg/dL; Participants with Gilbert syndrome may be included if their total bilirubin is =< 3.0; Aspartate aminotransferase (AST) =< 3 x the upper limit of normal (ULN); Alanine aminotransferase (ALT) =< 3 x ULN; Estimated creatinine clearance of >= 60 mL/min per the Cockcroft-Gault formula, and the participant is not on hemodialysis; Left ventricular ejection fraction >= 50% within 8 weeks before enrollment; Oxygen (O2) saturation > 92% not requiring oxygen supplementation; Women of childbearing potential (WOCBP): negative urine or serum pregnancy test; If the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required; Agreement by females and males of childbearing potential to use an effective method of birth control or abstain from heterosexual activity for the course of the study through at least 6 months after the last dose of protocol therapy; Childbearing potential defined as not being surgically sterilized (men and women) or have not been free from menses for > 1 year (women only); Research participants must have a potential donor or stem cell source identified for allogeneic transplantation, either related (7/8 or 8/8 allele matched or haploidentical); DONOR: The identified donor must be the original donor whose stem cells were used for the research participant's allogeneic hematopoietic stem cell transplantation (alloSCT); DONOR: The donor must be HIV negative; DONOR: KPS >= 70; DONOR: Documented body weight.

Exclusion: Prior allogeneic transplant if < 6 months prior to enrollment; Concurrent use of systemic steroids or chronic use of immunosuppressant medications should be stopped 28-days prior to enrollment. Recent or current use of inhaled or topical steroids in standard doses is not exclusionary. Physiologic replacement of steroids (prednisone =< 7.5 mg/day, or equivalent doses of other corticosteroids) is allowed; Participants with active autoimmune disease, including graft versus host disease (GvHD), requiring systemic immune suppressive should be stopped 28-days prior to enrollment; Participants may not be receiving any other investigational agents and are not dependent on concurrent biological therapy, chemotherapy, or radiation therapy; With exception to Hydrea which must be stopped prior to initiation of lymphodepletion; History of stroke or intracranial hemorrhage within 6 months prior to screening; Subjects with clinically significant arrhythmia or arrhythmias not stable on medical management within two weeks of screening if the patient is undergoing leukapheresis. Patients with controlled atrial arrythmia is allowed; Known bleeding disorders (e.g., von Willebrand's disease) or hemophilia; Subjects with presence of other active malignancy, however, research participants with history of prior malignancy treated with curative intent and in complete remission are eligible; Clinically significant uncontrolled illness; Active infection requiring antibiotics; Research participants who have tested human immunodeficiency virus (HIV) positive, or have active hepatitis B or C infection based on testing performed within 4 weeks of enrollment; Active viral hepatitis; Any other condition that would, in the Investigator's judgment, contraindicate the subject's participation in the clinical study due to safety concerns with clinical study procedures; Research participants on active systemic antifungal treatment within 8 weeks of enrollment are not eligible. However, participants on antifungal prophylaxis are eligible; Not applicable at the time of enrollment if the research participant's donor is undergoing leukapheresis; Subjects with >= Grade 2 myelofibrosis on bone marrow biopsy; Females only: Pregnant or breastfeeding; Prospective participants who, in the opinion of the investigator, may not be able to comply with all study procedures (including compliance issues related to feasibility/logistics).

ClinicalTrials.gov NCT05672147